We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
- Authors
Cooper, Todd M; Franklin, Janet; Gerbing, Robert B; Alonzo, Todd A; Hurwitz, Craig; Raimondi, Susana C; Hirsch, Betsy; Smith, Franklin O; Mathew, Prasad; Arceci, Robert J; Feusner, James; Iannone, Robert; Lavey, Robert S; Meshinchi, Soheil; Gamis, Alan
- Abstract
The development of antigen-targeted therapies may provide additional options to improve outcomes in children with acute myeloid leukemia (AML). The Children's Oncology Group AAML03P1 trial sought to determine the safety of adding 2 doses of gemtuzumab ozogamicin, a humanized anti-CD33 antibody-targeted agent, to intensive chemotherapy during remission induction and postremission intensification for children with de novo AML.
- Publication
Cancer, 2012, Vol 118, Issue 3, p761
- ISSN
1097-0142
- Publication type
Journal Article
- DOI
10.1002/cncr.26190